Sector
PharmaceuticalsOpen
₹1,368.9Prev. Close
₹1,359.4Turnover(Lac.)
₹5,073.33Day's High
₹1,414Day's Low
₹1,357.0552 Week's High
₹1,408.752 Week's Low
₹1,225Book Value
₹150.42Face Value
₹10Mkt Cap (₹ Cr.)
26,193.9P/E
152.71EPS
8.9Divi. Yield
0.14
The allotment of shares was finalised on July 8, and Emcure Pharma shares were scheduled to be listed on the BSE and NSE on July 10.
The IPO comprised a mix of fresh equity sale and an offer for sale (OFS).
The categories earmarked for NII and QIB investors received the most subscriptions, at 47.98 and 193.06 times, respectively.
The IPO is priced between Rs 960 and Rs 1008 a share, with buyers able to bid for 14 shares per lot.
According to BSE data, the initial share sale attracted bids for 1,80,40,960 shares, with 1,37,03,538 shares on offer.
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 180.85 | 180.85 | 180.85 | 180.85 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,661.02 | 1,531.68 | 2,120.92 | 1,733.7 |
Net Worth | 1,841.87 | 1,712.53 | 2,301.77 | 1,914.55 |
Minority Interest |
No Record Found
No Record Found
No Record Found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 6,658.25 | 5,985.81 | 5,855.39 | 6,056.42 | 5,048.55 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,658.25 | 5,985.81 | 5,855.39 | 6,056.42 | 5,048.55 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 56.99 | 45.91 | 63.47 | 35.39 | 82.31 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,775.75 | 150.91 | 4,20,027.58 | 237.82 | 0.77 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,855.95 | 78.49 | 1,30,370.29 | 430 | 0.61 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,574.55 | 32.24 | 1,28,058.81 | 1,055.94 | 0.82 | 3,752.25 | 346.4 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,178.7 | 27.87 | 1,21,729.16 | 1,700.8 | 0.25 | 4,035.4 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,954.5 | 28.24 | 1,16,346.95 | 1,417.2 | 0.57 | 5,823.9 | 1,458.7 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole Time Director
MUKUND KESHAO GURJAR
Whole Time Director
SUNIL RAJNIKANT MEHTA
Managing Director & CEO
SATISH RAMANLAL MEHTA
Chairman & Independent Directo
Berjis M Desai
Whole Time Director
NAMITA VIKAS THAPAR
Independent Director
P S Jayakumar
Independent Director
Vijay Gokhale
Independent Director
Vidya Rajiv Yeravdekar
Non Executive Director
Samonnoi Banerjee
Independent Director
Shailesh Ayyangar
Whole-time Director
SAMIT SATISH MEHTA
Company Sec. & Compli. Officer
CHETAN RAJENDRA SHARMA
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Emcure Pharmaceuticals Ltd
Summary
Emcure Pharmaceuticals Ltd. was originally incorporated as Emcure Pharmaceuticals Private Limited, as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited, through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.The Company is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure Pharmas were ranked as the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas. It has 14 manufacturing facilities across India, which are capable in producing pharmaceutical and biopharmaceutical products of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilized injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products. The Company keeps a strong track record in developing portfolios of differentiated products across several platforms, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far. In year 1999, Lasor Drugs Limited was amalgamated wit
Read More
What is the Emcure Pharmaceuticals Ltd share price today?
The Emcure Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1385.2 today.
What is the Market Cap of Emcure Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Emcure Pharmaceuticals Ltd is ₹26193.90 Cr. as of 23 Aug ‘24
What is the PE and PB ratio of Emcure Pharmaceuticals Ltd?
The PE and PB ratios of Emcure Pharmaceuticals Ltd is 152.71 and 9.72 as of 23 Aug ‘24
What is the 52 Week High and Low of Emcure Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Emcure Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Emcure Pharmaceuticals Ltd is ₹1225 and ₹1408.7 as of 23 Aug ‘24
What is the CAGR of Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at N/I%, 6 Month at N/I%, 3 Month at 0.02% and 1 Month at 2.72%.
What is the shareholding pattern of Emcure Pharmaceuticals Ltd?
The shareholding pattern of Emcure Pharmaceuticals Ltd is as follows:
Promoters - 78.08 %
Institutions - 5.09 %
Public - 16.82 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
